Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trophos, a pharma company specialising in therapies for orphan diseases including ALS, has launched MitoTarget Online, on behalf of the MitoTarget consortium.
Subscribe to our email newsletter
MitoTarget consortium said that the multilingual web-based resource aims to be the first point of call for all of those affected by ALS. The website contains detailed information on ALS and related subjects, and will host a comprehensive range of links enabling all those affected to find further information and support.
MitoTarget Online would also enable the ALS community to follow details of the major clinical trial being run by the MitoTarget Consortium. Currently, there are few drug trials in ALS.
Along with Trophos acting as co-ordinator, the MitoTarget consortium is backed by the EU and consists of 17 partners from four European countries (France, Germany, UK, and Belgium). A centre in Spain is also participating in the project.
Fourteen of the partners are participating in the clinical trial and five in research aimed at understanding the underlying mechanisms of ALS and other neurodegenerative diseases. These entities are among the leading ALS treatment and research centres in Western Europe, and are references for ALS diagnosis, treatment and care.
Damian Marron, CEO of the consortium leader at Trophos, said: “Trophos and the MitoTarget Consortium wish to develop treatments as quickly as possible for ALS, a rare but terrible and fatal disease. We want to make it as easy as possible for sufferers of the disease and for other people, including specialists, physicians, nurses, patients, and members of the public, to find out and share information. We hope this will speed up the process of finding cures, as well as help all those whose lives have been touched by this devastating disease.”